Skip to main content

Femasys Inc.

corporate_fare Company Profile

Femasys Inc.

FEMY·NASDAQ·Industrial Applications And Services·CIK 0001339005

The company is a U.S. manufacturer and a biomedical innovator focused on women's health. It develops and commercializes therapeutic and diagnostic products globally, with regulatory approvals in the U.S. and key international markets. Its product portfolio includes FemaSeed Intratubal Insemination, a U.S. FDA-cleared and internationally approved infertility treatment available in Europe, the United Kingdom, Canada, Israel, Australia, and New Zealand. FemSperm provides kits for in-office sperm preparation and analysis for use with FemaSeed. FemVue is a companion diagnostic for fallopian tube assessment via ultrasound, U.S. FDA-cleared and approved in Europe, the UK, Canada, Japan, Israel, Australia, and New Zealand. FemVue Controlled is a U.S. FDA-cleared diagnostic device that combines features of FemVue and FemChec technologies for multiple clinical uses, including confirming tubal patency before using FemaSeed. FemCerv is an endocervical tissue sampler for cervical cancer diagnosis, U.S. FDA-cleared and approved in Europe, the UK, Canada, Israel, and New Zealand. FemBloc is a permanent birth control solution that involves the minimally-invasive placement of a synthetic tissue adhesive into both fallopian tubes simultaneously, which degrades over time to produce nonfunctional scar tissue for permanent blockage.

Femasys Inc. (NASDAQ:FEMY) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 32 items for FEMY at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Femasys Proxy Reveals Director Resignation, New Appointments, and Related Party Compensation Amidst Going Concern Warning
  • Femasys Finalizes Proxy for Critical Shareholder Vote on Reverse Split and Dilutive Issuances to Avoid Delisting
  • Femasys Appoints Experienced COO John Canning Amidst Strategic Push
  • Femasys Reports $2.29M Revenue, $(0.47) Net Loss Per Share in 2025 10-K
  • Femasys 10-K Reveals Going Concern Doubt, Nasdaq Delisting Risk Amidst Heavy Dilution

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.29M
Net Income
-$18.63M
Diluted EPS
-$0.47
Op. Cash Flow
-$18.69M
Free Cash Flow
-$19.22M
Gross Profit
$1.42M
Operating Income
-$17.59M
Cash & Equivalents
$9.27M
Debt / Equity
0.00×
Net Margin
-8.12×
Shares Outstanding
59.6M sh
Source: 10-K · filed 2026-03-31 · accession 0001140361-26-012375
$1.24
52-week range · as of 2026-09-29 $1.24 – $22.2
Market cap
$10.73M
Volume
95.6K (0.9× avg)
3-mo avg 102.8K
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed FEMY - Filings & News (Page 2)

FEMY
Apr 30, 2026, 4:48 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.3725
Real-time Price: $1.24 info
Change: Reverse Stock Split info
Market Cap: $10.734M info
FEMY
Apr 06, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $0.4253
Real-time Price: $1.24 info
Change: Reverse Stock Split info
Market Cap: $10.734M info
FEMY
Apr 01, 2026, 9:13 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4325
Real-time Price: $1.24 info
Change: Reverse Stock Split info
Market Cap: $10.734M info
FEMY
Mar 31, 2026, 5:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.425
Real-time Price: $1.24 info
Change: Reverse Stock Split info
Market Cap: $10.734M info
FEMY
Mar 31, 2026, 5:04 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.4181
Real-time Price: $1.24 info
Change: Reverse Stock Split info
Market Cap: $10.734M info
FEMY
Mar 31, 2026, 4:38 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $0.425
Real-time Price: $1.24 info
Change: Reverse Stock Split info
Market Cap: $10.734M info
FEMY
Mar 31, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.425
Real-time Price: $1.24 info
Change: Reverse Stock Split info
Market Cap: $10.734M info
FEMY
Mar 27, 2026, 4:46 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $0.4709
Real-time Price: $1.24 info
Change: Reverse Stock Split info
Market Cap: $10.734M info
FEMY
Mar 20, 2026, 5:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5689
Real-time Price: $1.24 info
Change: Reverse Stock Split info
Market Cap: $10.734M info
FEMY
Mar 10, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.5117
Real-time Price: $1.24 info
Change: Reverse Stock Split info
Market Cap: $10.734M info
FEMY
Jan 15, 2026, 9:15 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.685
Real-time Price: $1.24 info
Change: Reverse Stock Split info
Market Cap: $10.734M info
FEMY
Jan 09, 2026, 7:52 PM EST
Filing Type: 424B3
Importance Score:
9
Price at Filing: $0.600
Real-time Price: $1.24 info
Change: Reverse Stock Split info
Market Cap: $10.734M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets